Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArcticZymes Technologies ASALTS:0DRV 76 Return-on-Tangible-Asset is 0.70% as of Mar. 2026, which is 76% below its 10-year median of 2.88. GuruFocus rates LTS:0DRV with a GF Score™ of 76/100 and a GF Value™ of kr24.00 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, ArcticZymes Technologies ASA ranks better than 86.35% on this metric.
The historical rank and industry rank for ArcticZymes Technologies ASA's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0DRV'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -32.43 Med: 2.88 Max: 55.7
Current: 4.35
During the past 13 years, ArcticZymes Technologies ASA's highest Return-on-Tangible-Asset was 55.70%. The lowest was -32.43%. And the median was 2.88%.
LTS:0DRV's Return-on-Tangible-Asset is ranked better than 86.35% of 1414
companies
in the Biotechnology industry
Industry Median: -35.66
vs LTS:0DRV: 4.35
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ArcticZymes Technologies ASA Return-on-Tangible-Asset Related Terms
ArcticZymes Technologies ASA Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.70% mean?
ArcticZymes Technologies ASA (LTS:0DRV) has a Return-on-Tangible-Asset of 0.70% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ArcticZymes Technologies ASA and its competitors. This is 76% below median its historical median of 2.88. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #193 out of 1414 companies in the Biotechnology industry, placing it in the top 13.6%.
Is ArcticZymes Technologies ASA's Return-on-Tangible-Asset too high?
ArcticZymes Technologies ASA's current Return-on-Tangible-Asset of 0.70% is 76% below median its 10-year median of 2.88. Based on the distribution chart, ArcticZymes Technologies ASA ranks #193 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #193 out of 1414 companies for Return-on-Tangible-Asset. This places ArcticZymes Technologies ASA in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current Return-on-Tangible-Asset is 0.70%, which is 76% below median its own 10-year median of 2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr24.00, compared to a current price of kr19.55 — trading 18.5% below its estimated fair value. The current Return-on-Tangible-Asset is 0.70%, which is 76% below median its 10-year median of 2.88. ArcticZymes Technologies ASA's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current Return-on-Tangible-Asset is 0.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr19.55 is trading 18.5% below its estimated GF Value™ of kr24.00.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
Return-on-Tangible-Asset: 0.70% (76% below median its 10-year median of 2.88)
GF Value™: kr24.00 vs. price of kr19.55 (18.5% below fair value)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
76GF Score
Get the complete analysis for LTS:0DRV
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
